MX2020004974A - Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett. - Google Patents
Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett.Info
- Publication number
- MX2020004974A MX2020004974A MX2020004974A MX2020004974A MX2020004974A MX 2020004974 A MX2020004974 A MX 2020004974A MX 2020004974 A MX2020004974 A MX 2020004974A MX 2020004974 A MX2020004974 A MX 2020004974A MX 2020004974 A MX2020004974 A MX 2020004974A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- reducing
- disorders including
- developmental disorders
- carbamate compound
- Prior art date
Links
- 208000009575 Angelman syndrome Diseases 0.000 title abstract 2
- 208000012239 Developmental disease Diseases 0.000 title abstract 2
- 208000001914 Fragile X syndrome Diseases 0.000 title abstract 2
- 208000006289 Rett Syndrome Diseases 0.000 title abstract 2
- -1 carbamate compound Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona a un uso de un compuesto de carbamato representado por la fórmula química 1, o una sal, un solvato o un hidrato farmacéuticamente aceptable del mismo para reducir a tratar trastornos del desarrollo que incluyen síndrome X frágil, síndrome de Angelman o síndrome de Rett.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170151251 | 2017-11-14 | ||
| PCT/KR2018/013765 WO2019098630A1 (ko) | 2017-11-14 | 2018-11-13 | 취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004974A true MX2020004974A (es) | 2020-08-24 |
Family
ID=66538693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004974A MX2020004974A (es) | 2017-11-14 | 2018-11-13 | Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200268711A1 (es) |
| EP (1) | EP3711761A4 (es) |
| JP (2) | JP7258902B2 (es) |
| KR (1) | KR102739605B1 (es) |
| CN (1) | CN111432814B (es) |
| AU (1) | AU2018370164B2 (es) |
| BR (1) | BR112020009255A2 (es) |
| CA (1) | CA3081224A1 (es) |
| IL (1) | IL274431B2 (es) |
| MX (1) | MX2020004974A (es) |
| WO (1) | WO2019098630A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200268711A1 (en) * | 2017-11-14 | 2020-08-27 | Sk Biopharmaceuticals Co., Ltd. | Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome |
| WO2019236938A1 (en) * | 2018-06-07 | 2019-12-12 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
| KR20240021189A (ko) * | 2021-06-11 | 2024-02-16 | 에스케이바이오팜 주식회사 | 자폐 스펙트럼 장애(asd)를 치료하는 방법 |
| JP2024169905A (ja) | 2023-05-26 | 2024-12-06 | キヤノン株式会社 | 再生制御装置及びその制御方法及びプログラム |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809620B1 (en) * | 2004-11-04 | 2010-12-29 | Addex Pharma SA | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| EP1921073A1 (en) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
| AU2009348523B2 (en) | 2009-06-22 | 2015-02-26 | Sk Biopharmaceuticals Co., Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| US9771335B2 (en) * | 2015-07-31 | 2017-09-26 | The Johns Hopkins University | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels |
| US9351968B1 (en) * | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| US11221329B2 (en) * | 2015-10-30 | 2022-01-11 | Lieber Institute, Inc. | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity |
| WO2018111002A1 (ko) * | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 카바메이트 화합물을 포함하는 구강 붕해 정제 |
| US20200268711A1 (en) | 2017-11-14 | 2020-08-27 | Sk Biopharmaceuticals Co., Ltd. | Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome |
-
2018
- 2018-11-13 US US16/763,660 patent/US20200268711A1/en active Pending
- 2018-11-13 EP EP18879735.1A patent/EP3711761A4/en active Pending
- 2018-11-13 WO PCT/KR2018/013765 patent/WO2019098630A1/ko not_active Ceased
- 2018-11-13 CN CN201880073916.6A patent/CN111432814B/zh active Active
- 2018-11-13 JP JP2020544728A patent/JP7258902B2/ja active Active
- 2018-11-13 AU AU2018370164A patent/AU2018370164B2/en active Active
- 2018-11-13 CA CA3081224A patent/CA3081224A1/en active Pending
- 2018-11-13 BR BR112020009255-0A patent/BR112020009255A2/pt not_active Application Discontinuation
- 2018-11-13 KR KR1020207013844A patent/KR102739605B1/ko active Active
- 2018-11-13 MX MX2020004974A patent/MX2020004974A/es unknown
- 2018-11-13 IL IL274431A patent/IL274431B2/en unknown
-
2023
- 2023-04-05 JP JP2023061122A patent/JP7588675B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018370164B2 (en) | 2024-08-15 |
| KR20200074154A (ko) | 2020-06-24 |
| CA3081224A1 (en) | 2019-05-23 |
| IL274431B1 (en) | 2024-02-01 |
| AU2018370164A1 (en) | 2020-05-21 |
| JP2021503011A (ja) | 2021-02-04 |
| EP3711761A1 (en) | 2020-09-23 |
| US20200268711A1 (en) | 2020-08-27 |
| JP7588675B2 (ja) | 2024-11-22 |
| KR102739605B1 (ko) | 2024-12-06 |
| IL274431B2 (en) | 2024-06-01 |
| IL274431A (en) | 2020-06-30 |
| JP7258902B2 (ja) | 2023-04-17 |
| JP2023086766A (ja) | 2023-06-22 |
| RU2020119296A3 (es) | 2022-02-09 |
| CN111432814A (zh) | 2020-07-17 |
| CN111432814B (zh) | 2024-05-14 |
| RU2020119296A (ru) | 2021-12-15 |
| BR112020009255A2 (pt) | 2020-10-20 |
| WO2019098630A1 (ko) | 2019-05-23 |
| EP3711761A4 (en) | 2021-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| ZA202000411B (en) | Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one | |
| PH12020551013A1 (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| MY208377A (en) | Compounds | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| PH12016501517B1 (en) | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors | |
| PH12017501422A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| MX2015017156A (es) | Inhibidores de bace. | |
| MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| IL274431A (en) | Use of a carbamate compound to reduce or treat developmental disorders including fragile X syndrome, Engelmann syndrome, or Rett syndrome | |
| MX2019001228A (es) | Metodo de produccion del compuesto de pirazol-amida. | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
| WO2015191681A3 (en) | Substituted pyridinones as mgat2 inhibitors | |
| NZ755298A (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| MX2020004972A (es) | Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia. | |
| AU2019408336A8 (en) | Phenylpyrrolidine compound and use thereof | |
| SA119400353B1 (ar) | مشتق بيرازول مستبدل | |
| MY208423A (en) | Composition of aminopyran derivative | |
| NZ748746A (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| WO2015117119A8 (en) | Synthesis of borane compounds |